

Appl. No. 10/510,125
Amdt. dated Sept. 26, 2008
Reply to Office Action of 7/3/2008

RECEIVED
CENTRAL FAX CENTER

SEP 29 2008

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) An absorbable, amphiphilic, solid copolyester stent coating composition for multifaceted prevention of vascular restenosis through a plurality of physcopharmacological modes comprising at least one bioactive compound and a segmented/block copolymer comprising a central polyoxyalkylene segment and at least one terminal segment ~~derived from~~ obtained from the ring-opening polymerization of at least one cyclic monomer, the copolymer further comprising at least one carboxyl group per chain.
2. (Original) An absorbable stent coating as set forth in claim 1 wherein the polyoxyalkylene segment comprises polyoxyethylene and wherein the chain comprises at least one carboxyl side group introduced by free-radically achieved maleation.
3. (Original) An absorbable stent coating as set forth in claim 1 wherein the polyoxyalkylene segment comprises polyoxyethylene and wherein the chain comprises at least one carboxyl end group introduced by acylation of the at least one terminal segment with glutaric anhydride.
4. (Original) An absorbable stent coating as set forth in claim 1 wherein the at least one bioactive compound comprises an antiangiogenic compound and a non-steroidal anti-inflammatory drug.

Appl. No. 10/510,125
Amdt. dated Sept. 26, 2008
Reply to Office Action of 7/3/2008

5. (Original) An absorbable stent coating as set forth in claim 1 wherein the at least one bioactive compound comprises an antineoplastic agent and a non-steroidal anti-inflammatory drug.
6. (Original) An absorbable stent coating as set forth in claim 1 wherein the at least one bioactive compound comprises an antineoplastic agent and an anti-platelet aggregation drug.
7. (Original) An absorbable stent coating as set forth in claim 1 wherein the at least one bioactive compound comprises an antiangiogenic agent and anti-platelet aggregation drug.
8. (Original) An absorbable stent coating as set forth in claim 1 wherein the at least one bioactive compound comprises paclitaxel and a non-steroidal anti-inflammatory drug.
9. (Original) An absorbable stent coating as set forth in claim 1 wherein the at least one bioactive compound comprises lanreotide and trapidil.
10. (Original) An absorbable stent coating as set forth in claim 9 wherein the lanreotide is at least partially conjugated ionically with the segmented/block copolymer.
11. (Original) An absorbable stent coating as set forth in claim 1 wherein the at least one bioactive compound comprises an ionic conjugate of a basic antiangiogenic peptide and an acidic non-steroidal anti-inflammatory drug.
12. (Original) An absorbable stent coating as set forth in claim 11 wherein the acidic non-steroidal anti-inflammatory drug comprises naproxen.

Appl. No. 10/510,125
Amdt. dated Sept. 26, 2008
Reply to Office Action of 7/3/2008

13. (Original) An absorbable stent coating as set forth in claim 12 wherein the basic antiangiogenic peptide comprises an LHRH analog.
14. (Currently amended) An absorbable stent coating as set forth in claim 12 wherein the basic antiangiogenic peptide comprises a somatostatin analog.
15. (Original) An absorbable stent coating as set forth in claim 1 wherein the at least one bioactive compound comprises an antiangiogenic peptide and an anti-platelet aggregation agent and wherein the antiangiogenic peptide and the anti-platelet aggregation agent are ionically conjugated with the segmented/block copolymer.
16. (Original) An absorbable stent coating as in set forth in claim 15 wherein the antiangiogenic peptide comprises lanreotide and the anti-platelet aggregation agent comprises trapidil.
17. (Original) A metallic endovascular stent coated with the absorbable stent coating of claim 1.
18. (Original) An absorbable endovascular stent coated with the absorbable stent coating of claim 1.
19. (New) An absorbable stent coating as set forth in claim 14 wherein the somatostatin comprises lanreotide.